Oman Pharmaceuticals and Healthcare Report

 Published On: Jul, 2015 |    No of Pages: 113 |  Published By: BMI Pharmaceuticals and Healthcare | Format: PDF
Request Free Sample

BMI View: Growth in Oman's pharmaceutical and healthcare market s will be driven by the roll out of medical insurance schemes and the completion of two medical cities , capitalising on the increased demand for healthcare services in both the domestic and international markets. Both projects are valued at over USD1bn each and will significantly improve the level of healthcare provision in Oman.

Headline Expenditure Projections
-Pharmaceuticals: OMR203mn (USD528mn) in 2014 to OMR217mn (USD564mn) in 2015; 6.8% in local currency and US dollar terms. Forecast broadly in line with Q 2 15.
-Healthcare: OMR853mn (USD2.22bn) in 2014 to OMR939mn (USD2.44bn) in 2015; +10.1% in local currency and US dollar terms. Forecast downgraded slightly from Q215.

Risk/Reward Index
Oman has limited longer-term commercial potential due to its small population and the fact that the government is responsible for the bulk of healthcare costs, which will increase the need for cost containment in the coming years. In Q315, Oman scores 49.0 out of 100 in the BMI Pharmaceutical Risk/Reward Index, which has seen the country maintain its position in 10th place in the Middle East and Africa matrix out of 31 countries.

Key Trends And Developments
-Data from the insurance sector in June 2015 indicated that claims paid by companies rose during Q115 by 36% to reach OMR39mn (USD101mn). Health insurance accounted for 22% of total direct premiums.
-The Ministry of Health launched the National Electronic Health Record System in May 2015. The system links a patient's files in affiliated health institutions so the patient can access their medical history at anytime from anywhere.
-Two paediatric drugs Advil and Panadol (marketed by GlaxoSmithKline) were recalled by the Ministry of Health in May 2015 due to errors in the dosage advice in their leaflets.

BMI Industry View7
SWOT9
Political11
Economic12
Operational Risk13
Industry Forecast15
Pharmaceutical Market Forecast15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Oman 2011-2019)17
Healthcare Market Forecast17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Oman 2011-2019)19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Oman 2011-2019)19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Oman 2011-2019)19
Prescription Drug Market Forecast20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Oman 2011-2019)21
Patented Drug Market Forecast22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Oman 2011-2019)23
Generic Drug Market Forecast23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Oman 2011-2019)25
OTC Medicine Market Forecast26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Oman 2011-2019)27
Pharmaceutical Trade Forecast28
Table: Pharmaceutical Trade Data And Forecasts (Oman 2013-2019)29
Table: Pharmaceutical Trade Data And Forecasts local currency (Oman 2013-2019)30
Other Healthcare Data31
Key Risks To BMI's Forecast Scenario32
Macroeconomic Forecasts34
Economic Analysis34
Table: OMAN - SELECTED INFRASTRUCTURE AND INDUSTRIAL PROJECTS39
Industry Risk Reward Indicies40
Middle East And Africa Risk/Reward Index40
Oman Risk/Reward Index48
Rewards48
Risks49
Market Overview50
Industry Trends And Developments51
Industry Trends And Developments51
Epidemiology51
Communicable Diseases51
Non-Communicable Diseases53
Healthcare Sector54
Public Healthcare Sector Developments56
Private Healthcare Sector Developments58
Table: Number Of Health Centres In Oman By Region In 201361
Table: Number And Type Of Health Institutions In Oman In 201361
Healthcare Insurance62
Telemedicine64
Medical Tourism64
Research And Development66
Clinical Trials67
Table: Clinical Trials In Oman68
Regulatory Development69
Regulatory Developments70
Intellectual Property Regime70
Regional Harmonisation71
Pricing And Reimbursement Regime72
Competitive Landscape76
Domestic Pharmaceutical Industry76
Foreign Pharmaceutical Industry77
Pharmaceutical Distribution79
Company Profile80
Zynova/Oman Pharmaceutical Products Company80
National Pharmaceutical Industries (NPI)83
Novartis86
GlaxoSmithKline89
Sanofi91
Johnson & Johnson93
Demographic Forecast95
Table: Population Headline Indicators (Oman 1990-2025)96
Table: Key Population Ratios (Oman 1990-2025)96
Table: Urban/Rural Population & Life Expectancy (Oman 1990-2025)97
Table: Population By Age Group (Oman 1990-2025)97
Table: Population By Age Group % (Oman 1990-2025)98
Glossary100
Methodology102
Pharmaceutical Expenditure Forecast Model102
Healthcare Expenditure Forecast Model102
Notes On Methodology103
Risk/Reward Index Methodology104
Index Overview105
Table: Pharmaceutical Risk/Reward Index Indicators105
Indicator Weightings106

If the above report does not have the information suitable for your business, we can provide custom research that can be lucrative for your business or enhance your profession.